APA (7th ed.) Citation

L, W., M, X., X, L., D, A., J, Y., & T, Q. (2024). A real-world pharmacovigilance study of KRAS G12C mutation inhibitors based on the food and drug administration adverse event reporting system. Frontiers in pharmacology, 15, 1418469. https://doi.org/10.3389/fphar.2024.1418469

Chicago Style (17th ed.) Citation

L, Wu, Xu M, Li X, Aierken D, Yu J, and Qin T. "A Real-world Pharmacovigilance Study of KRAS G12C Mutation Inhibitors Based on the Food and Drug Administration Adverse Event Reporting System." Frontiers in Pharmacology 15 (2024): 1418469. https://doi.org/10.3389/fphar.2024.1418469.

MLA (9th ed.) Citation

L, Wu, et al. "A Real-world Pharmacovigilance Study of KRAS G12C Mutation Inhibitors Based on the Food and Drug Administration Adverse Event Reporting System." Frontiers in Pharmacology, vol. 15, 2024, p. 1418469, https://doi.org/10.3389/fphar.2024.1418469.